Publications

Publications

Filtrer la liste des publications

Liste des publications

4 résultats

Image de lien PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus Durvalumab and FOLFIRI plus Durvalumab plus Tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. - 2022

Voir plus de détail

Image de lien Safety of FOLFIRI + Durvalumab +/- Tremelimumab in second line of patients with advanced gastric cancer: a safety run-in from the randomized phase II study DURIGAST PRODIGE 59 - 2022

Voir plus de détail

Image de lien PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus Durvalumab and FOLFIRI plus Durvalumab plus Tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. - 2022

Voir plus de détail

Image de lien PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI+Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer - 2020

Voir plus de détail